Overview

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-12-26

Target enrollment:

Participant gender:

Summary

This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.

Phase:

PHASE3

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

cagrilintide
semaglutide